This article refers to:
Article title: Efficacy and safety of peficitinib in rheumatoid arthritis
Author: Yuko Kaneko
Journal: Modern Rheumatology
DOI: https://www.tandfonline.com/doi/full/10.1080/14397595.2020.1794103
Please note the following correction to Figure 2.
The ACR50 achievement of the RAJ4 study was depicted incorrectly.
The corrected Figure 2 is given below.
Figure 2. ACR50 achievement of placebo and each peficitinib dose in the five randomized, placebo-controlled trials. RA21 and RA22 were global phase 2b trials. RAJ1 and RAJ4 were conducted in Japan, and RAJ3 was conducted in Japan, Korea, and Taiwan.
